GREY:MDCGF - Post by User
Post by
SCORPION17on Mar 08, 2011 12:17am
428 Views
Post# 18248960
Paradigm report
Paradigm reportHere's an exerpt.
Pandemic Vaccine Market
MDG’s H5N1 vaccine is the lead product in the company’s pipeline and given the current
status of its development, we believe it may generate revenue in 2012 from the U.S.
stockpiling program. Based on HHS plans to have enough vaccine to immunize 20M people
in the U.S. in the event of a pandemic, we believe the U.S. government’s goal is to maintain a
stockpile of ~40M doses. Assuming the vaccines in the stockpile expire every 18–24 months,
we estimate the annual market for adding to the stockpile is ~20M doses. We believe
Medicago will be chosen to contribute to the stockpile if its vaccine continues to generate
positive data in the Phase IIb trial, which is scheduled to be completed in Q2.